Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Descripción completa

Detalles Bibliográficos

Autores principales:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2020-07-01
Colección:	Endocrinology, Diabetes & Metabolism
Materias:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Acceso en línea:	https://doi.org/10.1002/edm2.159
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!